Clinical Practice Guidelines For the Management of Hepatocellular Carcinoma: A Systematic Review
- PMID: 37480425
- PMCID: PMC11096239
- DOI: 10.1007/s12029-023-00961-0
Clinical Practice Guidelines For the Management of Hepatocellular Carcinoma: A Systematic Review
Abstract
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, including Australia. The absence of a consensus clinical practice guideline (CPG) specific to HCC management poses challenges in reducing morbidity, mortality, and improving patient recovery. This systematic review aims to evaluate the existing evidence and assess the potential of published guidelines, including those with an international scope, to provide guidance for healthcare professionals in Australia.
Methods: Electronic search of MEDLINE, Embase, Cochrane Library, Google Scholar, and PubMed was conducted. Peer-reviewed English language articles from 2005 to June 2022 were included if they described management of HCC as part of an evidence-based overall management plan or CPG. The quality of the included CPGs was assessed by the Appraisal of Guidelines for Research and Evaluation II (AGREE II) tool.
Results: Twenty-one articles from 16 regions throughout the world were included in this review. All included guidelines (n = 21, 100%) recommended evaluating cirrhosis, hepatitis B, and hepatitis C as potential risk factors of HCC. Obesity and non-alcoholic fatty liver disease were recommended by 19 CPGs (91%) as risk factor for HCC. Fourteen guidelines (67%) endorsed using the BCLC staging system. Eighteen guidelines (86%) recommended a multidisciplinary approach for the management of HCC. Eighteen guidelines (86%) advised that surveillance using ultrasound should be implemented in all cirrhotic patients every 6 months regardless of the cause of cirrhosis. AGREE II mean overall assessment score was 90% indicating that all guidelines included were highly recommended in majority of domains.
Conclusions: The included CPGs provided a comprehensive approach, emphasizing the evaluation of risk factors, utilization of the BCLC staging system, and the importance of a multidisciplinary approach. Regular surveillance using ultrasound for cirrhotic patients was widely recommended. An understanding of contemporary international CPGs can prioritize aspects of the management of HCC to assist healthcare professionals to develop a national guideline to enable standardized, comprehensive, and evidence-based care for patients with HCC.
Keywords: Cancer; Clinical guidelines; Guidelines; HCC; Hepatocellular carcinoma; Liver.
© 2023. Crown.
Conflict of interest statement
The authors declare no competing interests.
Figures
Similar articles
-
Evaluation of the current guidelines for resection of hepatocellular carcinoma using the Appraisal of Guidelines for Research and Evaluation II instrument.J Hepatol. 2017 Nov;67(5):991-998. doi: 10.1016/j.jhep.2017.06.028. Epub 2017 Jul 8. J Hepatol. 2017. PMID: 28690176
-
Critical appraisal of clinical practice guidelines for diagnosis and treatment of hepatocellular carcinoma.J Gastroenterol Hepatol. 2011 Dec;26(12):1779-86. doi: 10.1111/j.1440-1746.2011.06891.x. J Gastroenterol Hepatol. 2011. PMID: 21875430 Free PMC article.
-
A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016.Clin Mol Hepatol. 2016 Mar;22(1):7-17. doi: 10.3350/cmh.2016.22.1.7. Epub 2016 Mar 28. Clin Mol Hepatol. 2016. PMID: 27044761 Free PMC article. Review.
-
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective.Clin Mol Hepatol. 2023 Apr;29(2):230-241. doi: 10.3350/cmh.2022.0421. Epub 2023 Jan 30. Clin Mol Hepatol. 2023. PMID: 36710607 Free PMC article. Review.
-
The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update.Biosci Trends. 2022 Mar 11;16(1):20-30. doi: 10.5582/bst.2022.01061. Epub 2022 Feb 24. Biosci Trends. 2022. PMID: 35197399 Review.
Cited by
-
Gene Expression Reprogramming by Citrate Supplementation Reduces HepG2 Cell Migration and Invasion.Int J Mol Sci. 2024 Jun 13;25(12):6509. doi: 10.3390/ijms25126509. Int J Mol Sci. 2024. PMID: 38928215 Free PMC article.
References
-
- Bosch FX, Ribes J, Borràs J. Epidemiology of primary liver cancer. In: Seminars in liver disease. © 1999 by Thieme Medical Publishers, Inc.; 1999. - PubMed
-
- Chen LT, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: A TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO MOS and SSO. Ann Oncol. 2020;31(3):334–351. doi: 10.1016/j.annonc.2019.12.001. - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical